Developing next generation
dermal injector device
– market ready 2016

Dermal Injector


Hair Regeneration

Partnership with Shiseido

4th largest cosmetics company worldwide


Ongoing tendon repair trial
– results expected in 2016

Tendon Repair


Ongoing skin rejuvenation trial
– results expected in 2016

Skin Rejuvenation


Our stock trades on the OTCQB
and on the TSX Venture Exchange


Learn more about investing in RepliCel below

Replicel Investor Relations

RepliCel is a regenerative medicine company focused on rejuvenating hair growth, restoring damaged skin, and repairing chronically injured tendons.  Each of these conditions is caused by a deficit of healthy, active cells required for normal healing and function.  The company’s autologous cell therapies address these cellular deficits with the injection of new cells manufactured for and delivered to address the specific clinical need.



Innovative technology delivering new solutions for chronic conditions

Large markets in aesthetics and orthopedics characterized by significant consumer demand

One of the few global regenerative medicine companies to have a Japanese partnership positioned to leverage the opportunity for expedited market approval now available in Japan

Strong intellectual property covering multiple aspects of the company’s technologies

Three imminent clinical trial starts with 2016 data readouts for tendon and skin

Partnership with Shiseido, 4th largest cosmetics company worldwide

Actively engaged in licensing and co-development deals over the next 24-months



RepliCel has three cellular products currently in clinical development designed to treat chronic tendon injuries, UV-damaged or aged skin and pattern baldness.  Each of these conditions is related to a deficit of a specific cell type which we believe is critical to the restoration of normal function.  The company is also developing a propriety, next-generation dermal injector designed to significantly improve the outcomes and patient experience around all dermal injections.


    RCT-01 Tendon Repair

    Phase 1/2 in chronic Achilles tendinosis: 2015
    (participant recruitment underway)

    RCS-01 Skin Rejuvenation

    Phase 1 in aged and UV-damaged skin: 2015
    (participant recruitment underway)

    RCH-01 Hair Regrowth

    Next phase clinical development: 2016

    RCI-02 Dermal Injector

    Prototype manufacturing and testing underway
    (CE mark clearance 2016)


    Innovative technology protected by both patents (issued and filed) and trade secrets on the cell isolation, product composition, manufacturing and clinical applications.


    Shiseido has an exclusive license and co-development commitment for RCH-01 in certain Asian countries including Japan, China and South Korea. The company is actively engaging potential partners for its other products.


    RepliCel uses a patient’s own cells to heal a variety of conditions linked to a lack of healthy cells necessary for normal healing and function.  RepliCel’s products are based on autologous (your own) cell therapies using cells isolated from a patient’s hair follicle. Two distinct cell populations are used. RepliCel believes these cells have unique applications for treating a variety of musculoskeletal and dermatological conditions.

Why Invest Now?

Markets – Three large markets: Orthopaedics, Dermatology & Pattern Baldness

Technology – Two distinct cell therapy platforms + 1 injector device

Strategy – Executing co-development partnerships to maximize value creation

Timing – Near-term clinical milestones, licensing opportunities and revenue generation






RCT-01 Achilles Tendinosis Product

RCT01Results from a clinical trial conducted by RepliCel collaborator, Dr. Connell, demonstrated the potential for RCT-01 to repair chronic micro-tears in the tendon. RepliCel’s phase 1/2 clinical trial, currently recruiting participants, is testing the use of RepliCel’s NBDS cells which are prolific producers of type 1 collagen – up to 5x more than skin-derived fibroblasts.

Goal: If RepliCel can successfully return a patient with a chronically injured tendon back to full function, without pain, it would be a game-changer in orthopedics particularly for athletes and military personnel but also for employment-related injuries – offering a way to permanently repair tendon injuries – getting people back on the field and back to work sooner.

RCS-01 Skin Rejuvenation Project

RCS01Based on the knowledge that RepliCel’s NBDS cells are prolific producers of type 1 collagen, RepliCel will be conducting a phase 1 human clinical trial in Germany investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin.  RepliCel believes that its product will address the inherent deficit of active fibroblasts required for the production of type 1 collagen, elastin and other critical extracellular dermal matrix components found in youthful skin.

Goal: To develop RCS-01 as natural-based dermal filler.  If successful, RepliCel believes that patients’ would prefer to inject their own cellular product vs hyaluronic acid to improve their skin’s vitality.

RCH-01 Pattern Baldness Product

RCH01Phase 1 human clinical trial results revealed that RCH-01 is a safe and effective treatment with the potential to increase hair density for those people suffering from pattern baldness. RCH-01 is a cell transplant procedure which replaces androgen sensitive cell populations responsible for hair growth with androgen-insensitive populations. Next phase clinical trials are designed to answer questions around the number of treatments required and the sustainability of results.

Goal: If RepliCel’s treatment successfully increases hair density by over 16% it would be considered the most promising minimally invasive, permanent solution for hair loss on the market.

RCI-02 Dermal Injection Device

RCH02A next-generation dermal injector designed to provide an improved level of control and precision for intradermal (dermis), subcutaneous (fat) or intramuscular injections.  The injector has broad application for dermatological injections of cellular products, fillers, hyaluronic acids, fat and collagen injections which would benefit from increased control over injection volumes and depth.  Prototypes are now being built to prepare for CE mark clearance to market the injector in Europe in 2016.

Goal:  To enable more consistent results and broader applications for all dermal injections.

View the Dermal Injector Fact Sheet here: RCI-02 Fact Sheet January 1-16


RepliCel Life Sciences Inc. Announces Closing of Warrant Incentive Program


VANCOUVER, BC – February 26, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce it has closed the warrant incentive program (the “Program”) announced on February 9, 2016, intended to encourage the exercise of outstanding common share purchase warrants of the Company expiring before June 30, 2016. 1,113,623 warrants were exercised in connection with the Program at an exercise price of $0.22 for gross proceeds totaling $244,997. 1,113,623 additional common share purchase warrants (each an “Incentive Warrant”) were granted in connection with the Program, with each Incentive Warrant entitling the holder to purchase one additional common share until 5:00 p.m. (Vancouver time) on February 25, 2018 at a price of $0.40 per share.

Read more on www.replicel.com

RepliCel Announces CEO Update

Milestones for 2016 include two clinical trial readouts, finalizing RCI-02 for a 2017 product launch, and initiation of Shiseido’s pattern baldness trial in Japan

VANCOUVER, January 11 2016 /CNW/ RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to provide an update to shareholders from its new President and CEO, Mr. R. Lee Buckler.

Read more on RepliCel.

RepliCel Receives European Patent for its Innovative Dermal Injector Technology

RCI-02 injector device promises the potential for unparalleled injection precision, the use of less anesthetic per procedure, and the enhanced treatment of fine wrinkles of the face, décolleté and hands.

VANCOUVER, January 11 2016 /CNW/ RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that it has been granted a patent (EP2623146) by the European Patent Office for its injection device technologies.

Read more on RepliCel.

RepliCel Announces Completion of First Injections in Clinical Trial of RCS-01 for Skin Aging and UV-Damaged Skin

VANCOUVER, BC – December 17, 2015 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today announced that the first injections of study products have been completed in the phase 1 clinical study (NCT02391935) evaluating RCS-01, an autologous cell-based skin rejuvenation product.

Read more on RepliCel‘s website.

RepliCel Executives to Present at 9th World Congress for Hair Research in Miami

VANCOUVER, BC – November 12, 2015 – RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, announced today that RepliCel’s Chief Medical Officer (CMO) and Chief Scientific Officer (CSO) – both founders of RepliCel’s technologies – will be presenting at the 9th World Congress for Hair Research taking place November 18-21, 2015 at the InterContinental Hotel Miami at 100 Chopin Plaza, Miami, Florida, USA. This year’s Congress theme is “Reflect, Rejuvenate, and REGENERATE,” with a program-focused goal of reflecting on current hair follicle regeneration knowledge, learning about the latest research in the field and developing new collaborations.

Read more on RepliCel.

Full List of Recent News